Drugs / Annexin A5
Annexin A5
also known as
Anchorin cii · Annexin v · Annexin-5 · Anxa5 · ANXV · Calphobindin i · Endonexin ii · Lipocortin v · +1 more
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05532735 | Aug 2022 → Jul 2024 | retinal vein occlusion | Annexin Pharmaceuticals AB | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05133791 Comparator | Sep 2021 → Jan 2024 | retinal vein occlusion | University Medical Center Groningen | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-02-06 | Annexin Pharmaceuticals AB | Results Database lock completed in Annexin’s Phase 2a study in RVO. Data confirms promising results – providing strong support for continued development of the drug candidate ANXV annexinpharma.com ↗
ANXV has demonstrated clinically relevant signals of effect and a continued favorable safety profile with no limiting treatment-related adverse events. |
| 2024-08-21 | Annexin Pharmaceuticals AB | Results Annexin reports promising topline results in RVO Phase 2a study annexinpharma.com ↗
Out of 14 subjects who received ANXV and were followed for 4 months, 12 improved or had stable disease with no or a single anti-VEGF treatment. |
| 2024-08-21 | Annexin Pharmaceuticals AB | Results Annexin rapporterar lovande topline-resultat från fas 2a-studien i RVO annexinpharma.com ↗
Annexin Pharmaceuticals AB meddelar idag topline-data från proof-of-concept fas 2a-studien som utvärderat ANXV-behandling i patienter med ögonsjukdomen retinal venocklusion (RVO). |
| 2018-05-31 | Annexin Pharmaceuticals AB | Results Holländsk preklinisk studie bekräftar potentialen för Annexin A5 vid behandling av hjärtinfarkt annexinpharma.com ↗
Forskare vid universitetet i Leiden, Nederländerna, har nyligen publicerat en studie som visar hjärtskyddande effekt av Annexin A5 i en preklinisk modell för behandling av hjärtinfarkt. |
All press releases naming this drug 8 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Annexin A5 | “ANXV (Annexin A5)” NCT05532735 ↗ |
| Known as | Anchorin cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | Annexin v | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | Annexin-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | Anxa5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | ANXV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05532735 ↗ |
| Known as | Calphobindin i | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | Endonexin ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | Lipocortin v | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Known as | Thromboplastin inhibitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095265 ↗ |
| Modality | Protein / enzyme biologic | “ANXV (Human recombinant Annexin A5 protein)” NCT05532735 ↗ |
| Route | Intravenous | “systemic intravenous injection” NCT05133791 ↗ |